QLGN Company Report

Qualigen Therapeutics, Inc. stockholders have approved all proposals with a majority vote, leading to a significant strategic transformation.
The company will officially rebrand as AIxCrypto Holdings, Inc. and begin trading under the new ticker symbol AIXC on November 20, 2025, marking a strategic shift from traditional biotechnology to a Web3-driven decentralized artificial intelligence technology platform.
Faraday Future Intelligent Electric Inc. is expected to become the majority and controlling shareholder with an estimated 55% direct equity ownership, increasing to approximately 63% including affiliated stockholders, and will nominate a majority of board seats.
Approved actions include the issuance of 337,432 common shares and 39,943 Series B convertible preferred shares as part of a Subscription Agreement, and approval to exceed Nasdaq's 19.99% issuance threshold.

Nov 17, 2025, 11:10 AM

8-K

Qualigen Therapeutics to Rename as AIxCrypto and Change Ticker to AIXC

QLGN

Proxy Vote Outcomes

New Projects/Investments

Earnings

QLGN will change its name to AIxCrypto and its stock ticker to AIXC on November 20, 2025, following stockholder approval, with Faraday Future Intelligent Electric Inc. (FFAI) becoming the majority and controlling stockholder with an initial direct ownership of about 55%.
Faraday Future (FF) and FX are adopting the North American Charging System (NACS) for future models, which will provide access to over 28,000 Tesla Superchargers.
FF reported a Q3 impairment amount of approximately $138 million, which accounted for roughly 67% of the total loss of a little over $206 million, with the operating loss excluding this one-time factor being $68 million.
FF achieved financing inflow greater than operating outflow for the sixth consecutive quarter, and its cash balance at the end of Q3 was the highest quarter-end level in nearly two years.
The company expects to file its Form 10-Q no later than November 19, citing increased workload and complexity from preparing consolidated financial statements for two public companies and ongoing valuation procedures.

Nov 17, 2025, 12:30 AM

Press Release

Qualigen Therapeutics (Faraday Future) Announces Production Milestones and Q3 2025 Earnings Call

QLGN

Product Launch

New Projects/Investments

Earnings

Faraday Future (FF), a company associated with Qualigen Therapeutics, announced that the first batch of FX Super One complete sets of parts is scheduled for shipment starting as early as November 15, 2025, with arrival at the Port of Long Beach by the end of November, initiating the pilot build and production phase and aiming for the first vehicle roll-off by year-end.
FF is scheduled to report its third quarter 2025 financial results after market close on Thursday, November 13, 2025, and will hold an earnings call that same day.
FF recently filed a utility patent application for a blockchain-and-Web3-based car sharing and short-term rental system.
Qualigen reported deploying $3 million in crypto assets under a hybrid "index + active management" strategy.

Nov 9, 2025, 11:54 PM

Press Release

Faraday Future Appoints Strategic Advisor, Reports Increased Institutional Ownership, and Strong FX Super One Preorders

QLGN

Management Change

New Projects/Investments

Product Launch

Faraday Future Intelligent Electric Inc. (FFAI) appointed Chris Nixon Cox as a Strategic Advisor to accelerate its "EAI + Crypto" Dual-Flywheel and Dual-Bridge Strategy.
Global asset management firm Vanguard increased its holdings to approximately 7.1 million FFAI shares in Q3, representing a 36% increase from the end of Q2.
Following the FX Super One Middle East Final Launch, the company secured non-refundable deposits and non-binding preorders for more than 200 units from three B2B partners.

Nov 3, 2025, 12:30 AM

Press Release

Qualigen Therapeutics to Rebrand as AIxCrypto and Outlines 2025 Strategic Goals

QLGN

New Projects/Investments

Product Launch

Qualigen Therapeutics (QLGN) announced it will rebrand as AIxCrypto following its stockholder meeting on November 12, 2025.
The company is launching new Web3 and crypto asset business initiatives, including the public beta of its BesTrade DeAI Agent by the end of November and the release of its EAI RWA Utility Token Whitepaper.
By the end of 2025, AIxCrypto aims to achieve three major milestones: expanding the C10 Treasury to $50 million AUM (which had $12 million in crypto asset allocations as of October 17), accelerating global growth of its BesTrade DeAI Agent, and launching crypto ecosystem tokens on leading exchanges.

Oct 28, 2025, 3:57 AM

Press Release

Faraday Future Provides Business Update on Finance, Investments, and Product Launch

QLGN

New Projects/Investments

Product Launch

Faraday Finance Inc. has been established and submitted its auto finance license application to the California Department of Financial Protection and Innovation, aiming to offer customized finance solutions for FF and FX users to enhance vehicle affordability and boost sales.
BlackRock increased its holdings in FFAI by approximately 26%, owning about 6.8 million common shares as of September 30, 2025, up from 5.38 million shares at the end of the previous quarter.
The FX Super One is scheduled for its Grand Launch in Dubai on October 28 at the Armani Hotel, Burj Khalifa, where the first global owner and Co-Creation Officer will be unveiled.
QLGN announced a strategic partnership with BitGo and initiated its first batch of C10 Treasury allocations, leading to a surge in daily trading volume to nearly $300 million the following day.

Oct 26, 2025, 11:30 PM

Press Release

Faraday Future Announces FX Super One Production Milestone and UAE Launch Date

QLGN

Product Launch

New Projects/Investments

Guidance Update

Faraday Future (FF) has achieved a significant production milestone for its FX Super One, having signed a procurement agreement for the first batch of complete parts, with shipment about to begin, and is targeting the year-end off-line production of its first vehicle.
The UAE launch of the FX Super One is scheduled for October 28 at the Armani Hotel, Burj Khalifa, Dubai.
FF has officially initiated its Q3 financial reporting process for both listed entities under its Dual Flywheel structure, with reports expected to be delivered on time.

Oct 19, 2025, 11:30 PM

Press Release

Qualigen Therapeutics Launches Cryptocurrency Asset Treasury Purchases

QLGN

New Projects/Investments

M&A

Qualigen Therapeutics, Inc. (QLGN) has officially launched C10 Cryptocurrency Asset Treasury (DAT) purchases, with strategic asset acquisitions scheduled to commence next week.
The company perceives the recent crypto market downturn as a strategic opportunity to acquire high-quality assets, leveraging its SMART Investment Framework.
The investment strategy includes an 80% passive allocation tracking the C10 Index (top 10 cryptocurrencies by market capitalization) and a 20% active allocation targeting core blue-chips such as Binance (BNB), Ethereum (ETH), and Solana (SOL), alongside high-growth leaders in AI, RWA, and oracles.
CXC10 also intends to pursue strategic mergers and acquisitions of technology-rich startups with limited cash flow to expand its industry footprint during the market correction.

Oct 13, 2025, 1:00 AM

Press Release

Qualigen Therapeutics to be rebranded as CXC10 and launch Crypto and Web3 business

QLGN

New Projects/Investments

Product Launch

Faraday Future (FF) successfully closed a strategic investment in Nasdaq-listed Qualigen Therapeutics (QLGN).
FF's $30 million investment in QLGN reflected a nearly 140% unrealized gain based on the closing price on the day of transaction closing.
If approved by stockholders, QLGN is expected to be rebranded as CXC10 and officially launch a new Crypto and Web3 business.
The new CXC10 company plans to focus on six core products under "Three Growth Engines," with its C10 Treasury expected to begin asset allocation on the Top 10 crypto coins next week.
YT Jia, Founder and Global Co-CEO of FF, will serve as Chief Advisor to the board of CXC10.

Oct 6, 2025, 12:00 AM

Press Release

Qualigen Therapeutics Closes $41 Million PIPE Financing and Announces Strategic Shift to Crypto

QLGN

Convertible Preferred Issuance

New Projects/Investments

Management Change

Qualigen Therapeutics, Inc. (QLGN) announced the successful closing of a $41 million private investment in public equity (PIPE) financing on September 29, 2025.
The financing was led by Faraday Future Intelligent Electric Inc. (FF), which invested $30 million and will hold approximately 55% of pro forma beneficial ownership.
The majority of the financing will be used to establish a new crypto business adventure, CXC10, as the company strategically transforms into a Web3- and crypto-focused entity; up to $6.8 million will fund existing debt and operations.
As part of this strategic investment, Jerry Wang was appointed Co-CEO and Koti Meka was appointed CFO of QLGN.